268 related articles for article (PubMed ID: 7296551)
1. Increased schedule-dependent synergism of vindesine versus vincristine in combination with methotrexate against L1210 leukemia.
Chello PL; Sirotnak FM
Cancer Treat Rep; 1981; 65(11-12):1049-53. PubMed ID: 7296551
[TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent synergism of methotrexate and vincristine against murine L1210 leukemia.
Chello PL; Sirotnak FM; Dorick DM; Moccio DM
Cancer Treat Rep; 1979; 63(11-12):1889-94. PubMed ID: 526921
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
5. Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo.
Bender RA; Nichols AP; Norton L; Simon RM
Cancer Treat Rep; 1978 Jul; 62(7):997-1003. PubMed ID: 688252
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
7. Effects of alpha-difluoromethylornithine alone and combined with adriamycin or vindesine on L1210 leukemia in mice, EMT6 solid tumors in mice, and solid tumors induced by injection of hepatoma tissue culture cells in rats.
Bartholeyns J; Koch-Weser J
Cancer Res; 1981 Dec; 41(12 Pt 1):5158-61. PubMed ID: 6796266
[TBL] [Abstract][Full Text] [Related]
8. Demonstration of a schedule-dependent therapeutic synergism utilizing the interacting drugs methotrexate and teniposide in L1210 leukemia.
Wampler GL; Carter WH; Campbell ED; Goldman ID
Cancer Treat Rep; 1987 Jun; 71(6):581-91. PubMed ID: 3581096
[TBL] [Abstract][Full Text] [Related]
9. Vinca-23-oyl amino acid derivatives: as new anticancer agents (review).
Bhushana Rao KS; Collard MP; Trouet A
Anticancer Res; 1985; 5(4):379-86. PubMed ID: 3898995
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells.
Howard SM; Theologides A; Sheppard JR
Cancer Res; 1980 Aug; 40(8 Pt 1):2695-700. PubMed ID: 6248211
[TBL] [Abstract][Full Text] [Related]
11. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Res; 1978 Feb; 38(2):345-53. PubMed ID: 304375
[TBL] [Abstract][Full Text] [Related]
12. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy.
Kris MG; Pablo D; Gralla RJ; Burke MT; Prestifilippo J; Lewin D
Cancer Treat Rep; 1984; 68(7-8):1029-31. PubMed ID: 6744336
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of L1210 leukemia with 5-azacytidine in combination with vincristine, adriamycin, or beta-cytosine arabinoside.
Presant CA; Vietti TJ; Valeriote F; Coulter DM
J Natl Cancer Inst; 1981 Dec; 67(6):1283-8. PubMed ID: 6171666
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of L1210 leukemia: comparison of 7 drugs given either continuously for 20 days, or in a single massive dose, early or late].
Mathé G; Schwarzenberg L; Hayat M; Schneider M
Rev Fr Etud Clin Biol; 1968 Dec; 13(10):951-60. PubMed ID: 5306738
[No Abstract] [Full Text] [Related]
17. Single versus combination chemotherapy of L1210 leukemia.
Koza I; Balázová E; Ujházy V
Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
[TBL] [Abstract][Full Text] [Related]
18. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
Avery TL; Roberts D
Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity of adriamycin combined with methotrexate against L1210 leukemia in mice.
Valeriote F; Vietti T; Coulter D
J Natl Cancer Inst; 1980 Apr; 64(4):801-5. PubMed ID: 6928994
[TBL] [Abstract][Full Text] [Related]
20. [A case of refractory acute lymphocytic leukemia who achieved a complete remission by mitoxantrone].
Yoshikawa H; Sao H; Tahara T; Akao Y; Yoshikawa S
Gan To Kagaku Ryoho; 1984 Mar; 11(3):515-20. PubMed ID: 6584088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
